<?xml version="1.0" encoding="UTF-8"?>
<collection xmlns="http://www.loc.gov/MARC21/slim">
 <record>
  <leader>     caa a22        4500</leader>
  <controlfield tag="001">465820808</controlfield>
  <controlfield tag="003">CHVBK</controlfield>
  <controlfield tag="005">20180323112135.0</controlfield>
  <controlfield tag="007">cr unu---uuuuu</controlfield>
  <controlfield tag="008">170327e19900301xx      s     000 0 eng  </controlfield>
  <datafield tag="024" ind1="7" ind2="0">
   <subfield code="a">10.1007/BF01233041</subfield>
   <subfield code="2">doi</subfield>
  </datafield>
  <datafield tag="035" ind1=" " ind2=" ">
   <subfield code="a">(NATIONALLICENCE)springer-10.1007/BF01233041</subfield>
  </datafield>
  <datafield tag="100" ind1="1" ind2=" ">
   <subfield code="a">Isfort</subfield>
   <subfield code="D">Robert</subfield>
   <subfield code="u">Miami Valley Laboratories, Genetic Toxicology Section, Human and Environmental Safety Divison, The Procter and Gamble Company, P.O. Box 398707, 45239-8707, Cincinnati, Ohio</subfield>
   <subfield code="4">aut</subfield>
  </datafield>
  <datafield tag="245" ind1="1" ind2="0">
   <subfield code="a">Frequency and mechanisms of factor independence in IL-3-dependent cell lines</subfield>
   <subfield code="h">[Elektronische Daten]</subfield>
   <subfield code="c">[Robert Isfort]</subfield>
  </datafield>
  <datafield tag="520" ind1="3" ind2=" ">
   <subfield code="a">Interleukin-3 (IL-3) -dependent cell lines were tested for spontaneous mutation frequency with respect to two markers, growth factor-independent growth and 8-azaguanineresistant growth. The mutation frequency for the growth factor-independent growth was approximately equal to that of 8-azaguanine-resistant growth. Investigation of the growth factor-independent phenotypes indicated that at least two different mechanisms for growth factor independence existed. One mechanisms was the activation of the IL-3 gene by mutation resulting in the constitutive expression of IL-3 and autocrine regulated growth. A second mechanisms results in IL-3-independent growth in a manner in which (1) constitutive tyrosine kinase activity was not seen and (2) c-myc transcription was constitutively activated. Interestingly, in these cells both the tyrosine phosphorylation and c-myc transcriptional pathways are still activatable following IL-3 stimulation. At present, the exact nature of the mutation that results in this phenotype is not known.</subfield>
  </datafield>
  <datafield tag="540" ind1=" " ind2=" ">
   <subfield code="a">Plenum Publishing Corporation, 1990</subfield>
  </datafield>
  <datafield tag="773" ind1="0" ind2=" ">
   <subfield code="t">Somatic Cell and Molecular Genetics</subfield>
   <subfield code="d">Kluwer Academic Publishers-Plenum Publishers</subfield>
   <subfield code="g">16/2(1990-03-01), 109-121</subfield>
   <subfield code="x">0740-7750</subfield>
   <subfield code="q">16:2&lt;109</subfield>
   <subfield code="1">1990</subfield>
   <subfield code="2">16</subfield>
   <subfield code="o">11188</subfield>
  </datafield>
  <datafield tag="856" ind1="4" ind2="0">
   <subfield code="u">https://doi.org/10.1007/BF01233041</subfield>
   <subfield code="q">text/html</subfield>
   <subfield code="z">Onlinezugriff via DOI</subfield>
  </datafield>
  <datafield tag="908" ind1=" " ind2=" ">
   <subfield code="D">1</subfield>
   <subfield code="a">research-article</subfield>
   <subfield code="2">jats</subfield>
  </datafield>
  <datafield tag="950" ind1=" " ind2=" ">
   <subfield code="B">NATIONALLICENCE</subfield>
   <subfield code="P">856</subfield>
   <subfield code="E">40</subfield>
   <subfield code="u">https://doi.org/10.1007/BF01233041</subfield>
   <subfield code="q">text/html</subfield>
   <subfield code="z">Onlinezugriff via DOI</subfield>
  </datafield>
  <datafield tag="950" ind1=" " ind2=" ">
   <subfield code="B">NATIONALLICENCE</subfield>
   <subfield code="P">100</subfield>
   <subfield code="E">1-</subfield>
   <subfield code="a">Isfort</subfield>
   <subfield code="D">Robert</subfield>
   <subfield code="u">Miami Valley Laboratories, Genetic Toxicology Section, Human and Environmental Safety Divison, The Procter and Gamble Company, P.O. Box 398707, 45239-8707, Cincinnati, Ohio</subfield>
   <subfield code="4">aut</subfield>
  </datafield>
  <datafield tag="950" ind1=" " ind2=" ">
   <subfield code="B">NATIONALLICENCE</subfield>
   <subfield code="P">773</subfield>
   <subfield code="E">0-</subfield>
   <subfield code="t">Somatic Cell and Molecular Genetics</subfield>
   <subfield code="d">Kluwer Academic Publishers-Plenum Publishers</subfield>
   <subfield code="g">16/2(1990-03-01), 109-121</subfield>
   <subfield code="x">0740-7750</subfield>
   <subfield code="q">16:2&lt;109</subfield>
   <subfield code="1">1990</subfield>
   <subfield code="2">16</subfield>
   <subfield code="o">11188</subfield>
  </datafield>
  <datafield tag="900" ind1=" " ind2="7">
   <subfield code="a">Metadata rights reserved</subfield>
   <subfield code="b">Springer special CC-BY-NC licence</subfield>
   <subfield code="2">nationallicence</subfield>
  </datafield>
  <datafield tag="986" ind1=" " ind2=" ">
   <subfield code="a">SWISSBIB</subfield>
   <subfield code="b">465820689</subfield>
  </datafield>
  <datafield tag="898" ind1=" " ind2=" ">
   <subfield code="a">BK010053</subfield>
   <subfield code="b">XK010053</subfield>
   <subfield code="c">XK010000</subfield>
  </datafield>
  <datafield tag="949" ind1=" " ind2=" ">
   <subfield code="B">NATIONALLICENCE</subfield>
   <subfield code="F">NATIONALLICENCE</subfield>
   <subfield code="b">NL-springer</subfield>
  </datafield>
 </record>
</collection>
